Immunotherapy in Oncology

An international team of authors published a systematic review addressing the relationship between the programmed cell death receptor ligand (PD-L1) and important clinical characteristics of patients with non-small cell lung cancer (NSCLC), the significance of PD-L1 expression for NSCLC prognosis, and the potential use of this biomarker to predict the response of patients with advanced/metastatic NSCLC to therapies targeting the PD-1/PD-L1 pathway.